Blog

At Gencove, our mission is to make genome sequencing accessible and interpretable. Over the past several weeks, it has become clear that a key missing piece of the response to the coronavirus crisis in the United States involves sequencing to monitor virus strains as they arise and spread. This was driven home by the identification of an apparently more contagious virus lineage in the UK and a potentially similar report from South Africa.

It seems certain that virus lineages with worrying properties (e.g. increased transmission or vaccine escape) are arising elsewhere in the world; these variants were only identified in the countries in question because they have systems for systematic viral surveillance by genome sequencing.

Users can now assign arbitrary JSON-formatted metadata to Gencove samples for downstream use.

We’ve been receiving consistent feedback from users saying they would like to store additional non-genomic data together with genomic data for their Gencove samples. These requests can be grouped into two broad clusters according to the nature of the data being stored:

• Phenotypic data about the individual represented by the sample
• Technical processing data
  • Batch information
  • Alternative or auxiliary identifiers

NEW YORK, March 13, 2019 /PRNewswire/ -- Gencove, the leading low-pass genome sequencing platform, announced today a $3 million investment led by Spero Ventures. Alexandria Venture Investments and Burst Capital participated in the round, along with existing investors Third Kind Venture Capital and Version One Ventures. The funding will be used to develop new applications for agricultural markets as well as expand Gencove's commercial operations in human genetics. Shripriya Mahesh, partner at Spero, will join Gencove's board of directors.